Redefining
Cancer
Treatment
The NHS in England has approved a ground-breaking new treatment for aggressive blood cancer, known as Lisocabtagene maraleucel (liso-cel or Breyanzi). This innovative therapy involves modifying a patient’s T-cells to specifically target and kill cancer cells, offering new hope to nearly 600 patients annually. The treatment has shown significant promise in clinical trials, delaying disease progression and potentially improving patients’ quality of life.
Blood cancer, particularly large B-cell lymphoma, is a fast-growing and challenging disease that affects certain white blood cells. Traditional treatments may not always be effective, leading to the need for more advanced therapies. Car T-cell therapy, like liso-cel, represents a significant advancement in cancer treatment, utilizing the patient’s own immune cells to fight the disease.
The approval of liso-cel by the NHS comes after the manufacturer, Bristol Myers Squibb, offered an improved commercial arrangement. This decision is expected to provide patients with more treatment options and potentially reduce the time spent in hospitals, as it can be administered as an outpatient treatment. The response from medical professionals and organizations like Blood Cancer UK has been overwhelmingly positive, highlighting the importance of continued research and investment in new treatments.
The availability of this treatment underscores the NHS’s commitment to providing the best possible care for cancer patients and marks a significant milestone in the fight against blood cancer.
Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment, Lisocabtagene maraleucel (also known as liso-cel or Breyanzi), which has been recommended for NHS use.
Recent scrutiny of figures like Steven Bartlett and Professor Thomas Seyfried highlights the challenges of balancing open dialogue with the
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
